Clinical Trials - August 10, 2016
AZ files mRNA clinical trial application
AstraZeneca has filed a Clinical Trial Application (CTA) with the Paul Ehrlich Institute and the German Federal Ministry of Health to initiate a Phase I clinical trial of AZD8601. The programme is part of a collaboration between AstraZeneca and Moderna to discover, develop and commercialise messenger mRNA (mRNA) TherapeuticsTM to treat serious cardiovascular, metabolic and […]
Career choice - July 6, 2016
Quality Assurance Microbiology
Ann-Britt Önnered and Linda Jervelius manage Quality Assurance at a microbiology laboratory and share their insights about maintaining a secure and hygienic laboratory environment, a crucial part of lab life.
Agreement - July 2, 2016
AZ in licensing agreement with LEO Pharma
AstraZeneca has entered into an agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease […]
Pharma Business - June 28, 2016
AZ’s new antibiotic approved in the EU
AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta(ceftazidime-avibactam, previously known as CAZ AVI), a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation. The approval includes intravenous use of Zavicefta for the treatment of adult patients suffering from complicated intra-abdominal infections (cIAI); Complicated […]
Agreement - June 16, 2016
AZ in commercialization agreement with Aspen
AstraZeneca has entered into a commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines – Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest). Under the terms of the […]
Uncategorized - June 14, 2016
Multi-million commitment to innovative production of biologics
The Swedish Industry and Innovation Minister, Mikael Damberg, notified last Thursday an upcoming commitment to innovative production of biopharmaceuticals within the framework of the life science collaboration program. “The government is contributing with 90 million SEK in order to create an unique innovation environment which will overcome the important shift from research to industrial production […]
